Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGFR Inhibition for Epithelial Solid Tumours: AZD4547 plus gemcitabine and cisplatin
2011-004072-10Phase 2Completed
- Sponsor
- University of Leeds
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fexagratinib in Epithelial neoplasm, transitional cell carcinoma (TCC) and bladder cancer (3 arms), sponsored by University of Leeds. Primary endpoints: Dose Escalation Cohort: primary endpoint and Randomized Expansion Cohort: efficacy. Started May 2012; status: completed.
02
Drugs
fexagratinib
03
Conditions
Epithelial neoplasmtransitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2011-004072-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004072-10.